Apalutamide Plus ADT Improves Outcomes in High-Risk Prostate Cancer: Mary-Ellen Taplin, MDByElla Hohmann, MS,Mary-Ellen Taplin, MD, FASCOJune 8th 2026
Dual-Target ADC Shows 15-Month Progression-Free Survival in Prostate Cancer: Tanya Dorff, MDByElla Hohmann, MS,Tanya Barauskas Dorff, MD, FASCOMay 31st 2026
ARACOG Trial Links Enzalutamide to Greater Cognitive Decline Compared With Darolutamide: Alicia Morgans, MD, MPHByElla Hohmann, MS,Alicia Morgans, MD, MPHMay 30th 2026
For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical TrialsByMary CaffreyMarch 3rd 2026
Radiopharmaceutical Medicare Use Jumps: ASTRO Abstracts Outline Delivery ModelsByMary CaffreyFebruary 20th 2026